Literature DB >> 1845780

Amiloride inhibition of human cytomegalovirus replication.

M Fons1, M Nokta, S Cerruti-Sola, T Albrecht.   

Abstract

Amiloride, an inhibitor of Na+/H+ exchange, interfered with cytomegalovirus (CMV) DNA synthesis, blocked the formation of nuclear inclusions, and reduced CMV infectious yields. The reduction of CMV infectious yields was concentration dependent with an ED90 of 46 microM. Amiloride at a concentration of 150 microM reduced CMV yields by about 100-fold. Reduction of infectious yields appeared to be related to interference with the formation of nuclear inclusions and to inhibition of CMV DNA synthesis. Nuclear inclusions were much reduced in size and demonstrated poorly defined cellulae in the amiloride-treated cells. CMV DNA synthesis was inhibited by approximately 70% when cells were treated with 150 microM amiloride. The reduction in CMV yields could not be related to the reported inhibitory effect of amiloride on protein synthesis. In amiloride (150 microM)-treated, CMV-infected cells, late, yet not immediate-early or early, protein synthesis was markedly decreased relative to untreated, CMV-infected cells. Accordingly, CMV DNA synthesis and the replication of CMV may be related to Na+ entry through an amiloride-sensitive pathway.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845780     DOI: 10.3181/00379727-196-43167

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  2 in total

1.  The chemokine receptor homologue encoded by US27 of human cytomegalovirus is heavily glycosylated and is present in infected human foreskin fibroblasts and enveloped virus particles.

Authors:  Barry J Margulies; Wade Gibson
Journal:  Virus Res       Date:  2006-09-08       Impact factor: 3.303

2.  The antifungal drug isavuconazole inhibits the replication of human cytomegalovirus (HCMV) and acts synergistically with anti-HCMV drugs.

Authors:  Beatrice Mercorelli; Marta Celegato; Anna Luganini; Giorgio Gribaudo; Galina I Lepesheva; Arianna Loregian
Journal:  Antiviral Res       Date:  2021-03-13       Impact factor: 5.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.